;

Non-Small Cell Lung Cancer (NSCLC) Market

Non-Small Cell Lung Cancer (NSCLC) Market By histology (large cell carcinoma, adenocarcinoma and SCC or squamous cell carcinoma); By treatment (chemotherapy, radiation and surgery)and Region -Analysis of Market Size, Share & Trends for 2014 - 2019 and Forecasts to 2030

Published on: Apr-2022
Report Code: FG HC 00048
No. of Pages: 170 - 350
Report Format: PDF

Product Overview

Non-Small Cell Lung Cancer (NSCLC) Market to surpass USD 33.5 billion by 2030 from USD 12.4 billion in 2021 at a CAGR of 11.70% throughout the forecast period 2021-30.

Small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC) are two main types of lung cancer NSCLC is the most common type of lung cancer accounting for approximately 85% of all lung cancers (IASLC, n.d.).Any epithelial lung cancer other than SCLC can be classified as NSCLC.NSCLC may be in the middle of the chest, but often also in other parts of the lung. Although NSCLCs are associated with smoking, they can also be found in patients who never have smoked. Adenocarcinomas are also common. Furthermore, chemotherapy and radiation therapy are fairly insensitive compared to SCLC.NSCLC comes from the central bronchial epithelial lung cells to the terminal alveoli. The histological type NSCLC coincides with the site of origin and reflects the variation in bronchial to alveoli respiratory epithelium. Whereas adenocarcinoma and bronchioloalveolar cancer typically originate from the peripheral lung tissue near central bronchuscommon symptoms include thoracic pain, wheezing, squatting, heartburn, chronic bronchitis, and loss of appetite, fatigue, shortness of respiration, bone pain, trouble swallowing, and limb stubbornness.

Market Highlights

Non-Small Cell Lung Cancer (NSCLC) Market is expected to project a CAGR of 11.70% during the forecast period, 2021-2030

The Non-Small Cell Lung Cancer (NSCLC) market is anticipated to grow on the back of opportunities generated by the advent of the rising total number of lung cancer globally out of which Non-Small Cell Lung Cancer (NSCLC) holds a significant share. This has attracted the majority of the key leaders to focus on advancing therapeutics and increasing the efficiencies of the existing ones. This market is also driven by the existing status of lung cancer as the most widely occurring disease and the increase in the number of deaths it has caused. Also, an increase in the investments by the key leaders in research and developments and the introduction of Non-Small Cell Lung Cancer (NSCLC) therapeutics into the major market players is boosting the market globally.

Global Non-Small Cell Lung Cancer (NSCLC) Market: Segments

The global Non-Small Cell Lung Cancer (NSCLC)market is based on  histology

In the middle of the lungs in squamous cells, the SCC is found near the bronchus. Large or undifferentiated cell type carcinomas occur in every part of the lung, they grow rapidly and are not easily treated. Adenocarcinoma is found in the cells responsible for mucous secretion outside the lung and is slower in growth compared with both other types.

Market Dynamics

Drivers

Rapid industrialization

Growing investment in the field of new drug research and development, rising emissions due to rapid industrialization, and increased smoker count are among the reasons why lung cancer is growing. This is why all of these factors drive market growth. According to a UK study from Cancer Research, the global incidence of cancer is increasing. The report shows that the cancer population will increase in the future. According to the report, there are expected to be 27.5 million new cancer cases in the world by 2040 if recent trends in the incidence of important cancers and population growth are consistent. This reflects a rise of 61.7% (17 million) compared to 2018. Thus, the incidence of NSCLC is expected to increase with the rise in cases of cancer. Increasing the demand for lung cancer therapeutics would help expand the market.

Restraints

Targeted therapy resistance

Targeted therapy resistance is a major issue within the NSCLC market as its potential is greatly reduced at the start of the acquired therapy resistance like Tarceva or Xalkori (crizotinib). Although pipeline activity is limited at the late stage of new molecular goals, new drugs are available to target EGFR and ALK to control resistance to increase patients' timelines for targeted therapy

The global Non-Small Cell Lung Cancer (NSCLC) market is further segmented by region into:

  • North America Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – the United States and Canada
  • Latin America Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – Mexico, Argentina, Brazil, and Rest of Latin America
  • Europe Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – United Kingdom, France, Germany, Italy, Spain, Belgium, Hungary, Luxembourg, Netherlands, Poland, NORDIC, Russia, Turkey, and Rest of Europe
  • APAC Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – India, China, South Korea, Japan, Malaysia, Indonesia, New Zealand, Australia, and the Rest of APAC
  • MENA Market Size, Share, Trends, Opportunities, Y-o-Y Growth,  CAGR – North Africa, Israel, GCC, South Africa

Global Non-Small Cell Lung Cancer (NSCLC) Market: Key Players

  • Rozlytrek (Entrectinib)

Company Overview, Business Strategy, Key Product Offerings, Financial Performance, Key Performance Indicators, Risk Analysis, Recent Development, Regional Presence, SWOT Analysis

  • Opdivo (Nivolumab)
  • Tagrisso (Osimertinib)
  • Vizimpro (Dacomitinib)
  • Portrazza (Necitumumab)
  • Imfinzi (Durvalumab)
  • Vitrakvi (Larotrectinib)

The global Non-Small Cell Lung Cancer (NSCLC) market report also contains an analysis on:

Global Non-Small Cell Lung Cancer (NSCLC) Market Segments

  • By histology
    • large cell carcinoma
    • adenocarcinoma
    • SCC or squamous cell carcinoma
  • By treatment
    • chemotherapy,
    • Radiation
    • surgery              
  • Global Non-Small Cell Lung Cancer (NSCLC) Market Dynamics
  • Global Non-Small Cell Lung Cancer (NSCLC) Market Size
  • Supply & Demand
  • Current Trends/Issues/Challenges
  • Competition & Companies Involved in the Market
  • Value Chain of the Market
  • Market Drivers and Restraints

Frequently Asked Questions (FAQ):

The Non-Small Cell Lung Cancer (NSCLC) Market size was estimated at USD 12.4 billion in 2021 and is expected to reach USD 33.5 billion by 2030

IBM Corporation, Health Fidelity, Wave Health Technologies, Lexalytics, Microsoft, Inovalon, AWS, Google, Dolby, and Cerner.

Histology and treatment are anticipated to hold the Non-Small Cell Lung Cancer (NSCLC) Market

Drivers Rapid industrialization

Small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC) are two main types of lung cancer NSCLC is the most common type of lung cancer accounting for approximately 85% of all lung cancers (IASLC, n.d.).Any epithelial lung cancer other than SCLC can be classified as NSCLC.NSCLC may be in the middle of the chest, but often also in other parts of the lung.

Select License Type

$3199

Report accessible by 1 user only

In case you require a hard copy, there will be an additional charge of $500. Please email us at info@fatposglobal.com with your request

Call us

Research Assistance

US : +1 (716) 218-3733
UK : +44 (208) 1235555



Select License Type

$3199

Report accessible by 1 user only

Sample Request

Client Testimonials

FATPOS CLIENT Appriciation DURING THE PROJECT

Clients